Isogenic Cell Lines Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Engineered on commonly used tumor cell lines that are highly relevant to diseases and drug targets Thorough molecular validation at genomic, transcript, and protein levels Additional bio-functional characterization with specific inhibitors to demonstrate drug-screening application Start your drug screening studies with the new isogenic cell line! NRAS mutant A375 Isogenic Cell Line NEW CRISPR/Cas9 Genome Editing Ap Note#25 Generation of EML4-ALK Isogenic Cell Line CRISPR, an advanced genome editing technology, enables precise modifications in the genomes of eukaryotic cells. Learn more about how ATCC created and validated the isogenic cell lines from the Application Note. Advanced Isogenic Cell Models EML4-ALK Fusion – A549 Isogenic Cell Line NRAS Q61K – A375 Isogenic Cell Line By utilizing the CRISPR/Cas9 gene editing, ATCC offers advanced isogenic cell models such as EML4-ALK fusion lung cancer cell line and BRAF inhibitor-resistant melanoma cell lines. These cell lines serve ideal in vitro models for anti-cancer drug screening. Parental Cell Lines Tumor Cell Panels Tumor Cells by Source Tissue Tumor Cells by Genetic Alteration A broad range of tumor cell lines and cell panels are offered by ATCC for the study of tumor biology, drug discovery applications, and high-throughput screening.